Is Genomic Health publicly traded?
In July 2005 Genomic Health filed for an initial public offering to sell up to US$75,000,000 in common stock.
When did Exact Sciences buy Genomic Health?
November 8, 2019
Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company. MADISON, Wis., November 8, 2019 – Exact Sciences Corp.
What does market cap mean on a stock?
Market cap—or market capitalization—refers to the total value of all a company’s shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares. For example, a company with 20 million shares selling at $50 a share would have a market cap of $1 billion.
Did exact sciences buy Genomic Health?
Exact Sciences Corp. is acquiring Genomic Health Inc. in a mammoth $2.8bn deal combining two of the world’s leading cancer diagnostics firms. Under the terms of the agreement, Exact Sciences will pay $72 per share in a cash and stock transaction expected to close by the end of 2019.
Who did Exact Sciences acquire?
In March 2020, Exact Sciences purchased Paradigm Diagnostics and Viomics, two companies based in Phoenix, Arizona that would expand their lab testing and research and development capabilities. Later, in October 2020, the company again announced a round of acquisitions – this time of Thrive Earlier Detection Corp.
Who acquired Genomic Health?
Exact Sciences Corp.
Exact Sciences Corp. is acquiring Genomic Health Inc. in a mammoth $2.8bn deal combining two of the world’s leading cancer diagnostics firms. Under the terms of the agreement, Exact Sciences will pay $72 per share in a cash and stock transaction expected to close by the end of 2019.
Is Oncotype DX FDA approved?
Although not formally approved by the US Food and Drug Administration (FDA), Oncotype DX is currently the only genomic assay recommended in treatment guidelines published by the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Center Network (NCCN) and is also recommended by both the …
What company owns Oncotype DX?
About Exact Sciences Corp. Building on the success of the Cologuard® and Oncotype DX® tests, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Exact Sciences unites visionary collaborators to help advance the fight against cancer.
How much does Oncotype DX cost?
The Oncotype DX test costs about $4,000. For insurance- and payment-related questions, call 1-866-ONCOTYPE (1-866-662-6897) or email [email protected].
How accurate is Oncotype DX test?
21-gene RS accurately predicted 97% of the low RS stratified patients to avoid receiving chemotherapy. However, addition of chemotherapy in the treatment regimen for node positive, Her-2/neu positive, high Ki-67, and PR negative tumors may be beneficial regardless of 21-gene RS.
Why is low market cap good?
In general, small-cap stocks have greater potential for price growth, because the companies themselves still have room to grow. However, they may also be riskier investments, because future performance is always unknown.
Who is the parent company of Cologuard?
Exact Sciences Corp. is a molecular diagnostics company specializing in the detection of early stage cancers. The company’s initial focus was on the early detection and prevention of colorectal cancer, in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer.
Who invented Cologuard?
(NASDAQ: EXAS) today announced Dr. David Ahlquist, co-inventor of Cologuard® and emeritus professor of medicine in the Division of Gastroenterology and Hepatology at Mayo Clinic, has been named a Fellow of the National Academy of Inventors (NAI).